Page 3 - Hematology Development News Today

 Phase III CANOPY-A trial did not meet primary endpoint of disease-free survival in patients with stages II-IIIA and IIIB completely resected non-small...

BASEL (dpa-AFX) - Swiss drug major Novartis AG (NVS) announced Monday that the Phase III CANOPY-A study evaluating adjuvant treatment with canakinumab (ACZ885) did not meet its primary endpoint

Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer

Scemblix® (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif®* (bosutinib) at 96...

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial

Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif* (bosutinib) at 96 weeks (37.6% vs. 15.8%), building on 24-week

Bristol Myers Squibb announced the withdrawal of the sBLA for luspatercept-aamt for the treatment of anemia in adults with NTD beta thalassemia.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company has withdrawn a supplemental biologics license application (sBLA) for Reblozyl® (luspatercept-aamt) for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia. The Company could not ap...

Analysis of HR+/HER2- patients treated in first-line with Kisqali plus fulvestrant demonstrated a significant OS benefit of nearly 16 months.

BASEL (dpa-AFX) - Novartis (NVS) reported positive topline results from an interim analysis of the phase III RATIONALE 306 study, which showed anti-PD-1 immune checkpoint inhibitor tislelizumab